Tandem CD19/CD22 Dual Targets CAR TCells Bridging Hematopoietic Stem Cells Transplantation Acquires Robust Remission for Relapsed and Refractory B Acute Lymphoblastic Leukemia Patients

被引：2

作者：

Cui, Wei ^{[1
]}

Zhang, Xinyue ^{[1
]}

Dai, Haiping ^{[1
]}

Cui, Qingya ^{[1
]}

Yin, Jia ^{[1
]}

Li, Zheng ^{[1
]}

Yu, Lei ^{[2
]}

Kang, Liqing ^{[2
]}

Wu, Depei ^{[1
]}

Tang, Xiaowen ^{[1
]}

机构：

[1] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis, Suzhou, Peoples R China

[2] Shanghai Unicar Therapy Biomed Technol Co Ltd, Shanghai, Peoples R China

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-152565

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1753

引用

页数：3

共 50 条

[1] Tandem CD19/CD22 Dual Targets CAR-T Cells Therapy Obtains Superior CR Rate Than Single CD19 CAR-T Cells Infusion As Well As Sequential CD19 and CD22 CAR-T Cells Infusion for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Patients
Liu, Sining
Zhang, Xinyue
Dai, Haiping
Cui, Qingya
Cui, Wei
Yin, Jia
Li, Zheng
Xue, Shengli
Yang, Chunxiu
Yang, Xiao
Qiu, Huiying
Miao, Miao
Chen, Suning
Jin, Zhengming
Fu, Chengcheng
Li, Caixia
Sun, Aining
Han, Yue
Wang, Ying
Yu, Lei
Wu, Depei
Tang, Xiaowen
BLOOD, 2021, 138
[2] CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial
Cordoba, Shaun
Onuoha, Shimobi
Thomas, Simon
Pignataro, Daniela Soriano
Hough, Rachael
Ghorashian, Sara
Vora, Ajay
Bonney, Denise
Veys, Paul
Rao, Kanchan
Lucchini, Giovanna
Chiesa, Robert
Chu, Jan
Clark, Liz
Fung, Mei Mei
Smith, Koval
Peticone, Carlotta
Al-Hajj, Muhammad
Baldan, Vania
Ferrari, Mathieu
Srivastava, Saket
Jha, Ram
Vargas, Frederick Arce
Duffy, Kevin
Day, William
Virgo, Paul
Wheeler, Lucy
Hancock, Jeremy
Farzaneh, Farzin
Domning, Sabine
Zhang, Yiyun
Khokhar, Nushmia Z.
Peddareddigari, Vijay G. R.
Wynn, Robert
Pule, Martin
Amrolia, Persis J.
NATURE MEDICINE, 2021, 27 (10) : 1797 - +
[3] CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial
Shaun Cordoba
Shimobi Onuoha
Simon Thomas
Daniela Soriano Pignataro
Rachael Hough
Sara Ghorashian
Ajay Vora
Denise Bonney
Paul Veys
Kanchan Rao
Giovanna Lucchini
Robert Chiesa
Jan Chu
Liz Clark
Mei Mei Fung
Koval Smith
Carlotta Peticone
Muhammad Al-Hajj
Vania Baldan
Mathieu Ferrari
Saket Srivastava
Ram Jha
Frederick Arce Vargas
Kevin Duffy
William Day
Paul Virgo
Lucy Wheeler
Jeremy Hancock
Farzin Farzaneh
Sabine Domning
Yiyun Zhang
Nushmia Z. Khokhar
Vijay G. R. Peddareddigari
Robert Wynn
Martin Pule
Persis J. Amrolia
Nature Medicine, 2021, 27 : 1797 - 1805
[4] Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
Dai, Hanren
Wu, Zhiqiang
Jia, Hejin
Tong, Chuan
Guo, Yelei
Ti, Dongdong
Han, Xiao
Liu, Yang
Zhang, Wenying
Wang, Chunmeng
Zhang, Yajing
Chen, Meixia
Yang, Qingming
Wang, Yao
Han, Weidong
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
[5] Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
Hanren Dai
Zhiqiang Wu
Hejin Jia
Chuan Tong
Yelei Guo
Dongdong Ti
Xiao Han
Yang Liu
Wenying Zhang
Chunmeng Wang
Yajing Zhang
Meixia Chen
Qingming Yang
Yao Wang
Weidong Han
Journal of Hematology & Oncology, 13
[6] Anti-CD19/CD22 Dual CAR-T Therapy for Refractory and Relapsed B-Cell Acute Lymphoblastic Leukemia
Yang, Junfang
Jiang, Pengfei
Zhang, Xian
Zhu, Xiaobin
Dong, Qi
He, Jiaping
Lin, Nanjing
Wang, Zhenguang
Cai, Songbai
Ye, Xun
Su, Yunchao
Li, Wenqian
Li, Jingjing
Yu, Ziyao
He, Jiujiang
Xu, Li
Song, Dan
Cao, Wei
Lu, Peihua
BLOOD, 2019, 134
[7] Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?
Sining Liu
Xinyue Zhang
Haiping Dai
Wei Cui
Jia Yin
Zheng Li
Xiao Yang
Chunxiu Yang
Shengli Xue
Huiying Qiu
Miao Miao
Suning Chen
Zhengming Jin
Chengcheng Fu
Caixia Li
Aining Sun
Yue Han
Ying Wang
Lei Yu
Depei Wu
Qingya Cui
Xiaowen Tang
Blood Cancer Journal, 13
[8] Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?
Liu, Sining
Zhang, Xinyue
Dai, Haiping
Cui, Wei
Yin, Jia
Li, Zheng
Yang, Xiao
Yang, Chunxiu
Xue, Shengli
Qiu, Huiying
Miao, Miao
Chen, Suning
Jin, Zhengming
Fu, Chengcheng
Li, Caixia
Sun, Aining
Han, Yue
Wang, Ying
Yu, Lei
Wu, Depei
Cui, Qingya
Tang, Xiaowen
BLOOD CANCER JOURNAL, 2023, 13 (01)
[9] Tandem CD19/CD22 Dual Targets CART Cells Therapy Acquires Superior CR Rate Than CD19 CAR-T Cells: A Case Controlled Study
Cui, Wei
Zhang, Xinyue
Dai, Haiping
Cui, Qingya
Song, Baoquan
Wu, Depei
Tang, Xiaowen
Yin, Jia
Li, Zheng
BLOOD, 2020, 136
[10] Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation
Liu, Shuangyou
Deng, Biping
Yin, Zhichao
Lin, Yuehui
An, Lihong
Liu, Dan
Pan, Jing
Yu, Xinjian
Chen, Bingzhen
Wu, Tong
Chang, Alex H.
Tong, Chunrong
AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (06) : 671 - 679

← 1 2 3 4 5 →